story of the week
Nivolumab for Patients With Advanced, Refractory Squamous NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Activity and Safety of Nivolumab, an Anti-PD-1 Immune Checkpoint Inhibitor, for Patients With Advanced, Refractory Squamous Non-Small-Cell Lung Cancer (CheckMate 063): A Phase 2, Single-Arm Trial
Lancet Oncol 2015 Feb 19;[EPub Ahead of Print], NA Rizvi, J Mazières, D Planchard, TE Stinchcombe, GK Dy, SJ Antonia, L Horn, H Lena, E Minenza, B Mennecier, GA Otterson, LT Campos, DR Gandara, BP Levy, SG Nair, G Zalcman, J Wolf, PJ Souquet, E Baldini, F Cappuzzo, C Chouaid, A Dowlati, R Sanborn, A Lopez-Chavez, C Grohe, RM Huber, CT Harbison, C Baudelet, BJ Lestini, SS RamalingamFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.